2 assets in Major Salivary Gland Carcinoma

Therapeutic assets addressing Major Salivary Gland Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Major Salivary Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Major Salivary Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)